Printer Friendly

/C O R R E C T I O N - SPI PHARMACEUTICALS/

 /C O R R E C T I O N - SPI PHARMACEUTICALS/
 In LA019, SPI Pharmaceuticals Declares Third Quarter Dividend,


moved earlier today, we are advised by the company that the first paragraph, fourth line, should read "to shareholders of record on Oct. 19, 1992. SPI Pharmaceuticals'" rather than "Oct. 15, 1992" as originally issued. The full corrected text of the original release follows:
 SPI PHARMACEUTICALS INC. DECLARES THIRD QUARTER DIVIDEND
 COSTA MESA, Calif. Oct. 8 /PRNewswire/ -- The board of directors of SPI Pharmaceuticals Inc. (AMEX: SPI) today declared a third quarter common stock dividend of 26 1/2 cents payable Oct. 30, 1992, to shareholders of record on Oct. 19, 1992. SPI Pharmaceuticals' annualized dividend is $1.06 per share.
 The company is currently in the process of seeking approval from the Securities and Exchange Commission of a dividend reinvestment plan which has been approved by its board of directors. Under terms of the plan, stockholders will have the option to receive cash or common stock of the company. Shareholders who choose stock will receive a premium of 3 percent additional shares.
 SPI Pharmaceuticals Inc. headquartered in Costa Mesa, manufactures, markets and distributes 600 prescription and non- prescription pharmaceuticals in more than 60 countries, including North and Latin America, Western and Eastern Europe and the Far East.
 -0- 10/8/92 C LA019
 /CONTACT: Paul Knopick of SPI Pharmaceuticals, 714-545-0100, ext. 2465/
 (SPI) CO: SPI Pharmaceuticals ST: California IN: MTC SU: DIV


EH-ML -- LA019X -- 7964 10/08/92 14:51 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 8, 1992
Words:252
Previous Article:CHEVRON CEO HIGHLIGHTS CONSEQUENCES FOR NORTHEAST OF REGULATORY BURDEN ON REFINERS
Next Article:MVMA REPORTS NEW TRUCK SALES FOR SEPTEMBER
Topics:


Related Articles
SPI PHARMACEUTICALS REPORTS RECORD NET INCOME AND SALES FOR THE YEAR ENDED 1991
SPI PHARMACEUTICALS DECLARES FOURTH QUARTER STOCK DIVIDEND EQUIVALENT TO TWENTY CENTS A SHARE
SPI PHARMACEUTICALS ANNOUNCES SECOND QUARTER DIVIDEND
IBM AND MULTI SOFT SIGN SOFTWARE MARKETING AGREEMENT
DCA ANNOUNCES SELECT COMM SERVER WITH PC ROUTER SUPPORT
RUSSIAN WORKERS PROVE KEEN STUDENTS OF CAPITALISM
CompuServe, Golden CommPass Team Up To Reach OS-2 Market
IBM Ships OS/390 2.7, Previews Future Releases.
Patients With HIV-Associated Wasting Gain More Weight With Concentrated Form of Megestrol Acetate, Study Shows.
Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters